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Abstract
Background: The influenza A(H1N1)2009 virus has been the dominant type of influenza A virus in Finland during the 2009–
2010 and 2010–2011 epidemic seasons. We analyzed the antigenic characteristics of several influenza A(H1N1)2009 viruses
isolated during the two influenza seasons by analyzing the amino acid sequences of the hemagglutinin (HA), modeling the
amino acid changes in the HA structure and measuring antibody responses induced by natural infection or influenza
vaccination.
Methods/Results: Based on the HA sequences of influenza A(H1N1)2009 viruses we selected 13 different strains for
antigenic characterization. The analysis included the vaccine virus, A/California/07/2009 and multiple California-like isolates
from 2009–2010 and 2010–2011 epidemic seasons. These viruses had two to five amino acid changes in their HA1 molecule.
The mutation(s) were located in antigenic sites Sa, Ca1, Ca2 and Cb region. Analysis of the antibody levels by
hemagglutination inhibition test (HI) indicated that vaccinated individuals and people who had experienced a natural
influenza A(H1N1)2009 virus infection showed good immune responses against the vaccine virus and most of the wild-type
viruses. However, one to two amino acid changes in the antigenic site Sa dramatically affected the ability of antibodies to
recognize these viruses. In contrast, the tested viruses were indistinguishable in regard to antibody recognition by the sera
from elderly individuals who had been exposed to the Spanish influenza or its descendant viruses during the early 20
th
century.
Conclusions: According to our results, one to two amino acid changes (N125D and/or N156K) in the major antigenic sites of
the hemagglutinin of influenza A(H1N1)2009 virus may lead to significant reduction in the ability of patient and vaccine sera
to recognize A(H1N1)2009 viruses.
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Introduction
During the recent two years, the pandemic influenza A virus
of swine origin, influenza A(H1N1)2009 virus, has been the
predominant circulating influenza virus in most parts of the world.
The virus has infected millions of people and the infection has lead
to the death of at least 18 400 individuals. In Finland the first cases
of the influenza A(H1N1)2009 were identified in May 2009.
During September the first local outbreaks occurred in garrisons
and schools, after which the virus spread rapidly in the general
population. The peak pandemic activity was observed during
weeks 43–49 and by the end of the year the epidemic was over in
Finland [1,2]. During the 2010–2011 epidemic season influenza
A(H1N1)2009 viruses were identified from the beginning of
December 2010 until middle of March 2011.
In serosurveys elderly individuals were found to have pre-
existing, cross-reactive antibodies against the novel 2009 pandemic
virus that were likely originating from previous infections with
antigenically related viruses such as the 1918 influenza virus and
its immediate descendants that were circulating during the early
decades of the 20
th century [3][4–8]. Except for the elderly, large
segments of the human population throughout the world lacked
protective immunity against the novel influenza A(H1N1)2009
virus and were thus susceptible to the virus infection. Until now,
likely due to limited immunological pressure in the general
population, the virus has not yet undergone significant genetic or
antigenic changes.
Through the hemagglutinin (HA) the influenza virus binds to
sialic-acid receptors on the host cell surface, after which the virus is
internalized and the viral genome enters the nucleus in order to
initiate viral RNA synthesis. Since the HA is situated on the surface
of the viral particles it is also a target for immune response, especially
antibodies.The major antigenic epitopes inthe HAmoleculemutate
frequently enabling the virus to escape immune responses. Recent
reports on the evolution of influenza A(H1N1)2009 describe
mutations S183P (amino acid numbering throughout the text starts
from the mature HA0 without signal peptide) and I191L in HA that
enhance viral replication in cell culture and in embryonated hens’
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been shown to be associated with a more virulent phenotype in
humans or mice [2,10–12]. The D127E and S183P mutations have
lead to antigenic changes and impaired recognition by ferret antisera
raisedagainstthe A/California/07/2009 virus [11]. Recently, a new
frequently observed mutation, E374K has been found [13]. This
mutation locates in the HA oligomerization interface and is also part
of a known antigenic site. This mutation is not unambiguously
associated with severe disease, but interestingly it has been detected
inpandemicvaccine breakthrough infections. These viruses typically
had N125D substitution in their HA molecule [14]. During the year
2010 viruses with double mutations N125D and E374K have been
found with increased frequency in the southern hemisphere [14].
These viruses have been associated with several vaccine break-
through infections and were identified in a number of fatal cases
[14]. The N125D mutation is located in the Sa epitope of
A(H1N1)2009 HA [2] and in an avian influenza strain (A/
Mallard/Pennsylvania/10218/84(H5N2)) the corresponding amino
acid was reported to cause antigenic drift as an immune escape
mutant [15]. However, antigenic analysis with ferret anti-sera
showed no remarkable differences in antibody titers against the
N125D virus as compared to the A/California/07/2009 vaccine
virus [14].
Genetic characterization of the influenza A(H1N1)2009 viruses
that circulated in Finland and elsewhere during 2009 show that
these viruses were closely related to A/California/07/2009 vaccine
virus [2,6,16]. At present, genetic analyses of the HA or neuramin-
idase (NA) genes do not reveal any changes that may have led to the
selection of a virus with increased epidemic potential or exception-
ally high virulence. However, the antigenic characteristics of these
viruses have not been systematically analyzed in humans. Here we
report that several amino acid changes, namely N125D, N156K,
S162R,andE374K,areassociated with reduced recognitionbysera
collected from patients having experienced natural A(H1N1)2009
infection or having received vaccination as analyzed by the
hemagglutination inhibition (HI) test. Especially, double mutations
N125D and N156K (2009 virus isolate) or N125D and E374K
(2010 virus isolates) were associated with declined antibody recog-
nition in vaccinated individuals.
Results
Analysis of amino acid sequences and prediction of the
structure of HA of influenza A(H1N1)2009 virus strains
In order to get a better understanding of the antigenic evolution
of recent pandemic A(H1N1)2009 viruses thorough characteriza-
tion of the HA gene of influenza A(H1N1)2009 viruses identified
in Finland during the epidemic seasons 2009–2010 and 2010–
2011 were carried out. Based on the sequence analysis and
comparisons of the HA molecules at the amino acid level the
viruses identified in the 2009–2010 season clustered in four genetic
groups I–IV/2009 [2] while the viruses identified during the
2010–2011 epidemic season formed three groups that are clearly
district from each other and the 2009–2010 viruses (Figure 1). The
viruses included in the phylogenetic tree shared no common
source of transmission in regard to location of virus isolation or
isolation date. A/Finland/554/2009 virus was one of the first
influenza A(H1N1)2009 viruses isolated in Finland in June 2009
[17]. Its HA nucleotide sequence is almost identical with that of
the A/California/07/2009 virus HA. The HA amino acid
sequences of representative Finnish A(H1N1)2009 viruses identi-
fied during the last two epidemic seasons were compared with the
vaccine strain, A/California/07/2009, and with the Spanish
influenza virus, A/South Carolina/1/1918, a human seasonal
A/H1N1 virus, A/Puerto Rico/8/1934, and the swine influenza
virus, A/New Jersey/8/1976, which caused an epidemic in a
garrison in Fort Dix in 1976. The amino acid alignment of HA
showed that influenza A(H1N1)2009 viruses, including the vaccine
strain, are very much alike (Figure S1). Compared to the vaccine
strain, the Finnish A(H1N1)2009 viruses have two to five amino
acid changes in their HA1 region, which are distributed to all the
major antigenic epitopes. One conserved change in all Finnish
A(H1N1)2009 virus strains, except A/Finland/554/2009, was
S203T which is located in the antigenic epitope Ca1 of HA, close
to the receptor binding pocket (Figure 2). This mutation has also
been detected globally in majority of influenza A(H1N1)2009
viruses [18]. In addition to this common change, most of the
Finnish A(H1N1)2009 viruses showed one or two additional amino
acid changes in other antigenic epitopes. Of potential interest in
respect to antibody recognition is the group I/2009–2010 virus,
A/Finland/694/2009, which has N125D and N156K amino acid
substitutions on the distal end of the HA molecule locating to the
antigenic site Sa (Figure 2 and Figure S2). In addition, novel
double mutations (N125D and E374K) were also found in the
group II/2010–2011 viruses, namely in A/Finland/19/2010 and
A/Finland/22/2010 viruses. The amino acid change E374K has
been identified in some A(H1N1)2009 viruses isolated in Finland
(Figure 1) and elsewhere [2,13,14]. Additional mutations at
potential antigenic sites, in relation to the California vaccine
virus, were also identified at positions 73, 74, 137, 162, 185, and
222 (Figure 2 and Figure S2).
Finnish influenza A(H1N1)2009 virus strains show
considerable antigenic heterogeneity
Sequence analysis of the HA gene revealed several amino acid
changes that have occurred in the viruses that circulated in
Finland during the 2009–2010 and 2010–2011 epidemic seasons.
By analyzing the nucleotide sequence and the molecular structure
of HA it is, however, difficult to estimate whether these changes
have any importance in antibody recognition. To analyze the
impact of amino acid changes on the antigenic characteristics of
circulating epidemic viruses we selected two representative viruses
from each of the four epidemic groups of the 2009–2010 viruses
and one to two viruses from the three epidemic groups of the
2010–2011 viruses (Figure 1). We determined antibody levels
against the thirteen Finnish influenza strains and the vaccine A/
California/07/2009 virus by HI test in a set of 120 serum samples
(Table 1). The 2010 (epidemic season 2010–2011) viruses were
tested in separate sets of analyses with the same panel of sera and
the data is therefore tabled separately (Table 1, upper and lower
panel, respectively). The vaccine strain, A/California/07/2009,
was used as a control in both analysis series and showed highly
reproducible mean antibody levels (Table 1; GMTs 28.5 and
29.9). The geometric mean titers obtained by HI test using
different virus isolates range from 14.7 to 38.9. The lowest
antibody titers were detected against the viruses with amino acid
changes in the Sa region of the HA e.g. A/Finland/694/2009, A/
Finland/618/2009 (Table 1) and A/Finland/19/2010, A/Fin-
land/22/2010 (Table 1). Some of the lowest antibody titers were
also observed against A/Finland/698/2009, which had amino
acid change in the antigenic epitope Cb (Figure 2 and Figure S2).
Antibody titers for cell culture-grown viruses correlate
with egg-propagated virus in HI test
All Finnish strains were isolated and propagated in Madin-Darby
canine kidney (MDCK) cells. For comparison we tested both
MDCK- and egg-grown vaccine strain, A/California/07/2009, in
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and egg-grown A/California/07/2009 were comparable although
analyses with egg-grown virus stocks gave somewhat higher
antibody levels (Table 1). The correlation coefficient for antibody
titers obtained by HI test varied between 0.55 and 0.96, which
indicateda strongpositivecorrelation between the vaccine virusand
Finnish epidemic strains (Figure 3A and B). Correlation coefficients
for all tested viruses were significant, p,0.001, which suggested
that MDCK- and egg-grown viruses were comparable in HI test.
However, the scatter blots in Figure 3 C showed that the corre-
lation between different viruses, especially Finland/694/2009,
Finland/6/2010, Finland/19/2010, and Finland/22/2010, is
better for sera with high antibody titers (.40) as compared to that
observed with sera having lower titers, where the spots (HI values)
seemed to be more dispersed.
The antibodies induced by natural infection with
influenza A(H1N1)2009 show differential recognition of
viruses with mutations in antigenic epitopes
The antibody titers against different influenza A(H1N1)2009
viruses differ notably. In order to analyze more carefully how the
sera from the different donor groups recognize influenza
Figure 2. Schematic representation of amino acid differences in the HA molecule between the Finnish influenza A(H1N1)2009
viruses and the vaccine virus, A/California/07/2009. In the middle, a side view of the trimeric structure of HA molecule of influenza
A(H1N1(2009) (A/California/04/2009; RCSB Protein Bank accession number 3LZG) with previously identified H1 protein-specific antigenic sites (Sai n
red, Sb in blue, Ca1 in darker green, Ca2 in lighter green and Cb in orange) of influenza A(H1N1) viruses and with the receptor binding pocket (RBP,
purple) is shown. Different monomers are shown in various shades of grey color. The amino acid changes of Finnish A(H1N1)2009 viruses compared
to A/California/07/2009, the vaccine strain, are illustrated in the trimeric HA structure. Amino acid changes in the antigenic sites are colored as inA /
California/07/2009 HA structure. Amino acid changes outside the antigenic sites are shown in yellow. Changes are illustrated by amino acid residue
number and with serial number of virus where the respective amino acid change has been observed.
doi:10.1371/journal.pone.0025848.g002
Figure 1. Phylogenetic tree of the HA of influenza A(H1N1)2009 strains. The strains included were identified in Finland during two epidemic
seasons, 2009–10 and 2010–2011. Some representative viruses from other parts of the world are included for comparison. All sequences included in
the phylogenetic tree constitute the entire 1698 nucleotide long coding region of HA. The horizontal lines are proportional to the number of
nucleotide changes. The phylogenetic tree was constructed using the Neighbor-Joining method with Mega software version 4. Viruses used in HI
tests are marked with yellow boxes. Signature amino acid changes are indicated with the colors which represent different antigenic epitopes of HA
(Sa in red, Sb in blue, Ca1 in dark green, Ca2 in lighter green and Cb in orange). Amino acid changes marked in black do not locate in expected
antigenic epitopes.
doi:10.1371/journal.pone.0025848.g001
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three groups: military conscripts with natural infection-induced
immunity [1] (Figure 4A), elderly individuals with cross-reactive
immunity against the pandemic virus [4] (Figure 4B), and indi-
viduals immunized with the pandemic influenza A(H1N1)2009
vaccine (Figure 5). Among military conscripts who had suffered a
natural influenza A(H1N1)2009 virus infection, the geometric
mean antibody titers against different viruses ranged between 20
and 105 (Figure 4A). The highest antibody titers (GMT 105) were
measured against A/Finland/619/2009, which was the virus that
was circulating in the Dragsvik garrison during the outbreak in
September 2009. The GMT against this virus formed the baseline
to which the responses against the other viruses were compared.
The other virus from the same group (II/2009–10) A/Finland/
634/2009 as well as A/California/07/2009 (egg-propagated), A/
Finland/20/2010 and A/Finland/22/2010 showed similar GMTs
in HI titrations. The antibody titers against the other viruses
included in these experiments differed statistically significantly or
highly significantly from the A/Finland/619/2009 virus-specific
responses. Patient anti-sera showed very poor recognition of A/
Finland/694/2009 virus (I/2009–10) (Figure 4A). A/Finland/
698/2009 (III/2009–10) and A/Finland/618/2009 (IV/2009–10)
also gave significantly lower antibody titers as compared to those
seen with A/Finland/619/2009 virus. The decrease in antibody
levels against A/Finland/694/2009, A/Finland/698/2009, and
A/Finland/618/2009 viruses, which exhibited mutations in
different antigenic epitopes (N125D and N156K, S74N, or
S162R, respectively; Figure 2 and Figure S2) showed that even
one or two amino acid change may significantly alter HI titers and
also have an effect on seroprotection rates. The seroprotection
rates (HI titer $40) were 56% lower for A/Finland/694/2009,
24% for A/Finland/698/2009, and 17% for A/Finland/618/
2009 compared to that of A/Finland/619/2009 virus (data not
shown).
The elderly have broad-spectrum low-level cross-reactive
antibodies against pandemic influenza viruses
We have previously reported that older Finns had cross-reactive
antibodies against the pandemic influenza A(H1N1)2009 virus
providing potential protection against the infection [4]. We tested
a set of serum samples collected in 2005 from individuals whose
age was at that time 80 years or over. Among these elderly
individuals the antibody titers against the current pandemic viruses
were generally low (range of GMTs 10–20). In addition, contrary
to patient sera where the antibodies failed to recognize some of the
tested viruses, in the elderly none of the tested viruses, except the
vaccine strains, were distinguishable in HI test (Figure 4B). This
may indicate that infections of the elderly by the Spanish influenza
and/or its immediate descendant viruses were able to induce quite
broad-spectrum cross-reactive humoral immunity against the
pandemic influenza A(H1N1)2009 virus. The significance of the
differences was not calculated since none of the studied viruses can
be set as a baseline. On the other hand, as compared to the A/
California/07/2009 vaccine virus the antibody titers against all
the Finnish strains were higher.
N125D and N156K mutations in Sa epitope of HA
compromise the antibody recognition induced by
vaccination with pandemic influenza A(H1N1)2009
vaccine
Natural infection with influenza A(H1N1)2009 virus (conscripts)
or past infection with Spanish influenza virus (elderly) seemed to
raise antibodies that recognized most of the viruses that circulated
in Finland during the 2009–2010 and 2010–2011 epidemic
seasons. However, viruses which had mutations in the Sa epitope
of HA (Figure 2) were more poorly recognized by the patient sera.
Next we analyzed how well antibodies, induced by vaccination
with the pandemic influenza A(H1N1)2009 vaccine, recognized
Table 1. The antibody geometric mean titers with 95% confidencial intervals (CI).
Virus strain group Amino acid changes* Geometric mean (95%CI)
A/California/7/09 E2 California-like 28.5 (22.6–35.9)
A/California/7/09 M3 California-like 24.0 (19.4–29.7)
A/Finland/554/09 California-like I321V, S451N 27.8 (22.9–33.7)
A/Finland/653/09 I/2009 S203T, I321V, N444K 31.5 (25.9–38.4)
A/Finland/694/09 I/2009 S203T,N125D,N156K, I321V, N444K 14.7 (12.8–16.8)
A/Finland/619/09 II/2009 S203T, D222E, I321V 33.9 (27.6–41.6)
A/Finland/634/09 II/2009 S203T,P137S, D222E, I321V 26.4 (21.3–32.6)
A/Finland/686/09 III/2009 S203T, I321V,L314MA493T 28.8 (23.6–35.2)
A/Finland/698/09 III/2009 S203T, S74N, I321V, L314 21.1 (17.8–25.1)
A/Finland/618/09 IV/2009 S203T, S162R 22.6 (18.7–27.4)
A/Finland/692/09 IV/2009 S203T, A73T 32.9 (26.9–40.2)
Virus strain group Amino acid changes* Geometric mean (95% CI)
A/California/7/09 E2 California-like 29.9 (22.6–37.1)
A/Finland/6/10 I/2010 S203T, I321V,A134T,S183P 33.1 (26.1–40.5)
A/Finland/19/10 II/2010 S203T, N125D, I321V, E374K, N462D 28.0 (22.5–33.3)
A/Finland/22/10 II/2010 S203T, N125D, I321V, E374K 26.4 (21.2–31.5)
A/Finland/20/10 III/2010 S203T, S185T, I321V,E374K,S451N,I460T 38.9 (30.2–47.8)
The antibody titers of a set of 120 sera were analyzed against A/California/07/2009 virus and thirteen pandemic influenza A(H1N1) 2009 viruses isolated in Finland
during 2009–2010 and 2010–2011 seasons. The group of each virus is determined by sequencing the hemagglutinin gene and it’s location in the phylogenetic tree.
*Amino acid changes, which locate in the surface of the HA molecule, as compared to A/California/7/09 virus.
doi:10.1371/journal.pone.0025848.t001
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PLoS ONE | www.plosone.org 5 October 2011 | Volume 6 | Issue 10 | e25848Figure 3. Correlation coefficiencies of the antibody titers between different virus isolates used in the HI test. The Pearson product moment
correlation coefficients (r) were calculated for all pairs for 2009–10 viruses (panel A) and for 2010–11 viruses (panel B). All correlation coefficients were significant
(p,0.01). C) The scatter plots and trend lines of antibody titers for each Finnish A(H1N1)2009 virus compared to the A/California/07/2009 vaccine virus.
doi:10.1371/journal.pone.0025848.g003
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sites can escape from vaccine-induced immunity. Analysis of serum
specimens from twenty vaccinated healthy adults showed that 21
days after vaccination anti-influenza antibodies showed a five to
fifteen-fold increase in geometric mean titers against all viruses,
except that of A/Finland/694/2009 with only less than a three-fold
increase (Figure 5A). One year after the vaccination, the mean
antibodylevelsagainstmoststudiedviruseshadclearlydecreasedbut
they were still three- to six- folds higher as compared to
prevaccination antibody levels. At 12 months post-vaccination A/
Finland/694/2009 virus-specific antibody levels were less than two-
fold higher over the prevaccination levels. In addition to A/Finland/
694/2009, also other viruses (698/2009, 618/2009, 19/2010 and
22/2010) with one or more mutations in the Sa or Cb regions
showed significantly lower mean antibody levels as compared to
homologous A/California/07/2009 vaccine virus suggesting that
minor changes in the surface structure of the HA molecule may
affect its immunogenic properties. Interestingly, however, also A/
Finland/554/2009 virus, which is almost identical to A/California/
07/2009, showed significantly lower antibody levels in the HI test.
Multiple immunizations of rabbits and guinea-pigs with
pandemic influenza A(H1N1)2009 vaccine induced high
antibody titers but failed to broaden the initial
cross-strain immunity
The vaccination of humans against the pandemic influenza
A(H1N1)2009 virus with the pandemic influenza A(H1N1)2009
vaccine is usually comprised by one vaccine dose. To analyze
whether multiple immunizations would dramatically enhance
vaccine induced antibody levels and cross-reactivity against different
epidemic A(H1N1)2009 virus strains, we immunized rabbits and
guinea pigs up to four times with pandemic influenza A(H1N1)2009
vaccine (Pandemrix, GlaxoSmithKline). Analysis of the mean
antibody responses in rabbits (Figure 6A) indicates that the vaccine
inducesveryhighantibodylevelsbutformostofthevirusesthemean
antibody levels reach their maximal or near-maximal levels already
after two immunizations. Additional immunizations did not enhance
the cross-reactivity of the antibodies against different A(H1N1)2009
strains, since the relative antibody ratios in comparison to vaccine
virus were not increased during repeated immunizations (Figure 6A
and data not shown). The lowest cross-reactive antibody levels in
Figure 4. Geometric mean titers of anti-A(H1N1)2009 virus antibodies among military conscripts and the elderly. A) Serum samples
from military conscripts (Dragsvik garrison) who had undergone a natural influenza A(H1N1)2009 virus infection (n=40) were analyzed by HI test and
geometric mean titers (+/2 95% confidence intervals, CI) for each virus were calculated. The significance of differences between A/Finland/619/09
and other viruses (California-like, viruses from groups I–IV/2009–10, and viruses from groups I–III/2010–11) were calculated using Student’s paired t-
test, * p,0.01, ** p,0.001, *** p,0.0001. The index virus, A/Finland/619/09 (bolded) was isolated from Dragsvik garrison during the outbreak in
September 2009. B) The serum samples collected before pandemic in 2004–2005 from the elderly people (80 years of age or over) were analyzed by
HI test and geometric mean titers (+/2 95% CI) for each virus were calculated.
doi:10.1371/journal.pone.0025848.g004
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specimens and included viruses A/Finland/554/2009, A/Finland/
694/2009, A/Finland/618/2009, A/Finland/698/2009, A/Fin-
land/19/2010 and A/Finland/22/2010 (Figures 5 and 6A) further
emphasizing true antigenic differences in these viruses as compared
to the A/California/07/2009 vaccine virus.
Serum specimens from guinea pigs were collected only at day 0
before the first immunization and one week after the last
vaccination. Mean antibody levels increased to very high levels
after four doses of vaccine and antibody titers against most viruses
were at a comparable level. The only exception was again the
A/Finland/694/2009 virus, against which the antibodies re-
mained at much lower level as compared to other viruses
(Figure 6B). This suggests that even multiple doses of the vaccine
failed to induce highly cross-reactive antibodies against this virus
which carries two mutations in antigenic site Sa (Figure 2 and
Figure S2).
Discussion
Genetic characterization of influenza A(H1N1)2009 viruses re-
vealed that virus strains detected in Finland during the 2009–2010
Figure 5. Geometric mean titers of anti-influenza A(H1N1)2009 virus antibodies among pandemic influenza-vaccinated individuals.
The serum samples from persons vaccinated with one dose of pandemic influenza A(H1N1)2009 virus vaccine were collected on day 0 (black dots), on
day 21 (open circles), and one year after the vaccination (grey triangles) and analyzed by HI test with viruses detected in Finland during influenza
seasons 2009–10 (A) and 2010–11 (B). Geometric mean titers (+/2 95% CI) for each virus were calculated. The significance of differences between the
egg-grown vaccine virus A/California/07/2009 (Cal E2)-specific antibody responses and multiple Finnish pandemic virus isolates were calculated using
Student’s t-test, * p,0.01, ** p,0.001, *** p,0.0001.
doi:10.1371/journal.pone.0025848.g005
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2011 seasonal virusesinclude three clusters.Thedifferentclustersfrom
the epidemic season 2009–2010 and 2010–2011 were distributed as
follows I/2009–10 15%, II/2009–10 12%, III/2009–10 11%, IV/
2009–10 22%, I/2010–11 22%, II/2010–11 57%, and III 2010–11
20%, respectively. The 2010–2011 Finnish epidemic viruses resemble
those that have been found in the Southern hemisphere, Central and
Far East Asia, North America, and in Europe. Thus the viruses used in
the present study are well representative of globally circulating
pandemic A(H1N1)2009 viruses. Comparison of the amino acid
sequences of the HA proteins of Finnish A(H1N1)2009 viruses to the
A/California/07/2009 vaccine virus HA showed that these viruses
have three to eight amino acid changes, of which two to five amino
acid changes are located in the most variable parts of the HA
molecule, i.e. HA1 region. Molecular characterization of influenza
A(H1N1)2009 viruses indicate quite typical (1–1.5% of amino acids
per year) rates of evolution and antigenic drift during the past and
most recent epidemic seasons [2,11,16,19]. Although the genetic
heterogeneity observed among influenza A(H1N1)2009 viruses has
been wide, antigenically the viruses have been closely related to the
vaccine virus A/California/07/2009. Therefore, the initial pandemic
A/California/07/2009 virus remained the WHO recommended
Figure 6. Geometric mean titers of anti-A(H1N1)2009 virus antibodies receiving multiple doses of pandemic influenza A(H1N1)
vaccine in rabbits and guinea pigs. Rabbits (A) and guinea pigs (B) were immunized four times at three weeks intervals with pandemic influenza
A(H1N1) vaccine and the serum samples were collected on day 0 (rabbits and guinea pigs), before each immunization (rabbits), and one week after
the last immunization (rabbits and guinea pigs). The immunizations (black) and sample collections (grey) are marked with arrows. The serum samples
were analyzed by HI test and geometric mean titers for each virus were calculated. The means represent the geometric means of three rabbit and five
guinea pig anti-sera.
doi:10.1371/journal.pone.0025848.g006
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northern hemisphere. This virus is still assumed to give reasonable
protection against infection with globally circulating viruses. However,
even few amino acid changes in antigenically important sites of the
HA, as demonstrated in the present study, may render the vaccine
virus a poor match to the circulating virus strains.
The HA protein on the surface of influenza virions is one of the
major target molecules for host antibody responses. Therefore,
amino acid changes occurring either in the antigenic sites or on the
surface of the HA molecule may have an important effect on
antibody recognition. Five classical antigenic sites (Sa, Sb, Ca1,
Ca2, and Cb) have been described in the HA of influenza A/
H1N1 virus [20,21]. These antigenic sites are located at the
globular head of the HA (Figures 1, 2, and S2) although recent
studies have described antigenically important determinants also
in the stem region of HA [22–24]. At present, there is no
experimental proof that the antigenic sites found in the HA
molecule of classical seasonal H1N1 HA molecules are equally
important for the immunity against recent pandemic
A(H1N1)2009 viruses. However, our results showed that only
one amino acid change in the antigenic site Sa (N125D)
compromised antibody recognition, which could be seen as
reduced antibody titers in the HI test. This amino acid change
is characteristic of group II/2010–11 viruses, which represents the
majority of Finnish viruses (57%) from the epidemic season 2010–
11. If there was another amino acid change (N156K) in the Sa
epitope, as was the case in the A/Finland/694/2009 virus (Figure 2
and Figure S2), the antibody titers were even lower. From all the
analyzed viruses (222 strains; data not shown) A/Finland/694/
2009 represent the only virus (0.5%) with this double amino acid
change. This decrease in antibody titers was seen both in
individuals who experienced a natural influenza A(H1N1)2009
infection or who were vaccinated with the pandemic influenza
A(H1N1)2009 vaccine. Interestingly, elderly individuals, who were
likely infected with the 1918 Spanish influenza and/or its
descendant viruses in the early decades of the 20
th century,
seemed to have low level cross-reactive antibodies against the
pandemic A(H1N1)2009 viruses. This cross-reactivity was not
sensitive to minor amino acid changes in specific antigenic
epitopes, since sera collected from these pre-immune elderly
individuals recognized different types of viruses almost equally
well.
One of the first outbreaks of influenza A(H1N1)2009 in Finland
occurred in the Dragsvik garrison in Southern Finland during
September 2009. This outbreak led to the infection of more than
50% of the conscripts as judged by the presence of anti-influenza
A(H1N1)2009 virus antibodies after the outbreak [1]. It was very
likely that only one virus (A/Finland/619/2009 strain) caused this
early outbreak and thus the antibody responses induced by the
epidemic virus lead to good recognition of other early pandemic
influenza A(H1N1)2009 viruses, such as the A/California/07/
2009 vaccine virus and the May 2009 isolate, A/Finland/554/
2009. Viruses isolated later during the epidemic, such as the strains
A/Finland/694/2009 (changes at positions N125D, N156K and
S203T), A/Finland/618/2009 (changes at positions S162R and
S203T) and A/Finland/698/2009 (changes at positions S74N and
S203T), which showed dual or triple mutations in antigenic sites
(Figure 2 and S2) showed impaired recognition by patient
convalescent sera. This suggests that relatively strong immune
response induced by natural infection might be evaded by only a
few mutations in critical antigenic regions. The same effect was
also seen among vaccinated individuals, since antibody responses
against the above described viruses (694, 618 and 698) were
significantly reduced as compared to the homologous vaccine virus
strain (Figure 5A). In addition, post-vaccination anti sera showed
reduced recognition of epidemic season 2010–2011 viruses A/
Finland/19/2010 and A/Finland/22/2010, which showed point
mutations in antigenic sites Sa (N125D) and Ca1 (S203T). This
further suggests that the specificity of humoral immune responses
induced by natural infection and vaccination are alike. In addition,
the mean HI titers seen among the vaccinees and those individuals
who had undergone a natural infection are comparable (Figure 4A
vs. Figure 5) thus indicating that the pandemic influenza
A(H1N1)2009 vaccine (Pandemrix) is capable of inducing very
good humoral immunity. It is also noteworthy that portion of
antibodies that neutralize or in other ways inhibit virus replication
may not be detected in HI test. The presence of such antibodies
and the possible alterations in antibody recognition of the viruses
under discussion would be interesting to analyze in further studies.
An interesting observation in the present study was that three out
of four 2010–2011 season viruses had an E374K mutation in the
HA2 region (A/Finland/19/2010, A/Finland/20/10, and A/
Finland/22/10). Viruses with the same mutation predominated in
Oceania during local winter 2010, e.g. the southern hemisphere
influenza season 2010 [14]. Barr and coworkers also reported that
viruses carrying the N125D and E374K mutations were found in
vaccine breakthrough cases in teenagers and adults, who had been
vaccinated with the monovalent pandemic influenza A(H1N1)2009
vaccine andthesamemutant viruses werealso foundina numberof
fatal cases. However, the two Finnish strains (A/Finland/19/2010
and A/Finland/22/2010) with this dual mutation, representing the
epidemic season 2010–2011 group II/10 viruses, were isolated from
unvaccinated individuals.
An important question is whether antibody levels and the
broadness of cross-reactivity against different virus strains can be
stimulated by repeated immunizations with pandemic influenza
A(H1N1)2009 vaccine. Since the Finnish population received only
one dose of the pandemic vaccine before or during the pandemic
we used experimental animals to study the effect of repeated
immunizations on antibody responses and cross-reactivity. In
rabbits, it was found that already two doses of the pandemic
influenza A(H1N1)2009 vaccine were sufficient to induce maximal
or near-maximal antibody responses against different epidemic
virus strains. Interestingly, repeated immunizations were not able
to expand the cross-reactivity against different viruses since the
antibody ratios against different virus isolates vs. the vaccine virus
strain remained rather constant (Figure 6A). This may indicate
that the initial specificity of the antibody response is determined at
early times of immunization and repeated immunizations with the
same vaccine, such as the Pandemrix vaccine, does not lead to
broadening of the specificity of the antibody response. These
findings may indicate that also in humans, in order to induce
better antibody cross-reactivity, the composition of the vaccine has
to be changed rather than giving repeated immunizations with the
same vaccine.
The present study demonstrates that circulating influenza
A(H1N1)2009 viruses are genetically highly diverse and at present
a specific globally circulating virus strain has not been observed.
Genetic characterization of the Finnish circulating viruses, which
originated from different parts of the world, indicates that the
evolutionary speed of the virus is quite typical for influenza A
viruses. However, there appears to be a tendency that many
viruses have mutations in antigenically important epitopes of the
HA molecule and these mutations may have quite dramatic effects
on antibody recognition both among vaccinated individuals and
those that had experienced a natural infection. Thus, continuous
genetic and antigenic surveillance of circulating influenza viruses
as well as rapid and open sharing of information is of utmost
Antigenic Properties of Influenza A(H1N1)2009
PLoS ONE | www.plosone.org 10 October 2011 | Volume 6 | Issue 10 | e25848importance for WHO to make the best possible recommendation
for the vaccine viruses. In addition, it is important to rapidly
identify virus strains with elevated virulence or with the ability to
escape vaccine- or natural infection-induced immunity.
Materials and Methods
Viruses
All viruses for serological analysis were selected based on their
HA gene nucleotide sequence. We have previously reported that
based on the HA gene, influenza A(H1N1)2009 viruses circulating
in Finland during 2009–2010 season clustered in four genetic
groups [2]. Two representatives of each of these four groups were
selected for immunological analyses: A/Finland/618/2009, A/
Finland/619/2009, A/Finland/634/2009, A/Finland/653/2009,
A/Finland/686/2009 A/Finland/692/2009 A/Finland/694/
2009, and A/Finland/698/2009. One additional virus, A/Fin-
land/554/2009 [17], which was one of the first influenza
A(H1N1)2009 viruses isolated in Finland in 2009 and is very
closely related to the A/California/07/2009 vaccine virus, was
also included in the analyses. Four more recent viruses, A/
Finland/6/2010, A/Finland/19/2010, A/Finland/20/2010 and
A/Finland/22/2010, were chosen for analyses to represent the
epidemic season 2010–2011. All viruses were propagated in
MDCK cells and stored in aliquots at 280uC. For comparison A/
California/07/2009 was also grown in embryonated hens’ eggs
since the pandemic influenza A(H1N1) vaccine was prepared from
an egg-grown virus.
Serum specimens
In order to get a broader view of the antigenic characteristics of
the selected viruses, we chose three different sets of serum
specimens for serological analysis. The first set of sera was from 20
healthy adults who received pandemic influenza A(H1N1) vaccine
Pandemrix in November 2009. Pandemrix is a monovalent split-virion
vaccine generated from the A/California/07/2009-like strain
(NYMC X-179A; New York Medical College) by GlaxoSmith-
Kline (GSK) Biologicals [25]. A single dose of this vaccine contains
3.75 mg of HA and AS03 adjuvant. Serum samples from 20
volunteers (median age 42; range 27 to 62 years) were collected
prior to vaccination on day 0, day 21, and one year after the
vaccination. The second set of sera was collected from 50
unvaccinated military conscripts (median age 21; range 20–28)
in the Dragsvik garrison (Raasepori), which is located in Southern
Finland. An outbreak of influenza A(H1N1)2009 virus occurred in
this garrison during September 2009 and 50% of the conscripts
were infected (confirmed by PCR) with influenza A(H1N1)2009
[1]. For the present study we chose 40 A(H1N1)2009 virus
seropositive and 10 seronegative randomly selected serum
specimens. The third set of serum samples was obtained from
the virus diagnostic unit at the Central Laboratory Services of the
Helsinki University Hospital (HUSLAB). These sera had been
collected prior to influenza A(H1N1)2009 pandemic in 2004–2005
and the specimens have been randomly selected from all sera sent
to HUSLAB from different parts of the country. The samples were
anonymous, only the age of the donor and sample collection date
was known. For the present study, 50 serum samples from elderly
individuals representing the age group of 80 years or older were
chosen, since our previous observations indicated that these
individuals have cross-reactive antibodies against influenza
A(H1N1)2009 virus [4].
The collection of serum samples for the present study was
approved by the Ethical Committee of the Helsinki-Uusimaa
Health District (Permissions 382/E5/07 148/2008 and 1289/2010
and 199/13/03/00/2009 1164). All individuals participating in the
studies (vaccinated and conscripts) gave written informed consent
before enrolment in the study.
Sequence and phylogenetic analysis of HA gene
The nucleotide sequences of the influenza A(H1N1)2009 viruses
for this study (35 Finnish strains from the epidemic season 2010–
2011) were sequenced from original clinical samples. RNA
extraction, cDNA synthesis, DNA amplification and sequencing
were performed as previously described [2]. The nucleotide
sequences of the complete HA genes were assembled using
Sequencer version 4.7 (Gene Codes Corporation, Ann Arbor,
USA). Mega software version 4 [26] (Molecular Evolutionary
Genetics Analysis) was used in nucleotide and amino acid
sequence comparison and for the construction of the phylogenetic
tree. The Neighbor-joining method [27] with the maximum
composite likelihood model [28] was used to generate the
phylogenetic tree. Bootstrapping was performed with 1000
replicates [29]. In the present study all HA amino acid residues
are numbered without the signal peptide sequence.
GenBank accession numbers of the HA sequences of the Finnish
virus strains from the epidemic season 2009–2010 are GQ283488,
GU292341, HQ228034, HQ228037, HQ228039-40, HQ228042,
HQ228053-4, HQ228057, HQ228059-60, HQ228067-8, HQ228074,
HQ228076, HQ228078-80, HQ228083-4, HQ228086, HQ228090-1,
HQ228093-6, HQ228098, HQ228103-4, HQ228107, HQ228109,
HQ228111, HQ228113-4, HQ228118, HQ228120-1, HQ228125,
HQ228127, HQ228129, HQ228131, HQ228133-4, HQ228137-8,
HQ228140, HQ228142, and HQ228144-7 and from the season
2010–2011 they are JN601076-JN601110. The GenBank accession
number for the vaccine strain, A/California/07/2009 is FJ966974.
Supplemental sequences for the phylogenetic tree were obtained
from GISAID EpiFlu
TMDatabase. Identification codes of supple-
mental sequences are listed in Figure S3. The GenBank accession
number for A/South Carolina/1/18 is AF117241, for A/Puerto
Rico/8/1934 CY033577 and for A/New Jersey/8/1976 CY039991.
Theclinicalsamplesforisolationofvirusesincluded inthisstudyhave
beencollected for routine viral diagnostic purposes.Based onnational
laws ethical permission are not required for specific microbiological
diagnostics and further characterization of detected viruses.
Structural analysis of amino acid differences in the HA
molecule
The three-dimensional structure of the HA molecule of
influenza A(H1N1)2009 virus, A/California/04/2009 (RCSB
Protein Bank accession number 3LZG) was used to locate amino
acid differences between the Finnish A(H1N1)2009 viruses
(seasons 2009–2010 and 2010–2011) and the A/California/07/
2009 vaccine virus. The molecular models were constructed using
RasMol Molecular Graphics software version 2.7.3 [30].
Immunizations of rabbits and guinea pigs
In order to study the immunogenicity and the ability of the
pandemic influenza A(H1N1)2009 vaccine to induce cross-reactive
antibody responses in animals we immunized five guinea pigs and
three rabbits four times in three weeks intervals. Each animal
received one human dose (3,75 mg HA in AS03 adjuvant) of
vaccine with each immunization. Serum samples from guinea pigs
were collected before the first immunization (day 0) and one week
after the last immunization (day 70). From the rabbits serum
samples were collected on day 0, before each immunization on
days 21, 42, and 63, and one week after the last immunization on
day 70. Immunizations of the animals and the collection of serum
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Institute for Health and Welfare (permission KTL 2008-02).
Serum samples were stored at 220uC and analyzed for influenza
A virus specific antibodies by the HI test.
Serologic assays
All serum specimens were assayed by the HI test against nine
influenza A(H1N1)2009 strains isolated in Finland during the
2009–2010 epidemic season, four Finnish influenza A(H1N1)2009
strains from season 2010–2011, and A/California/07/2009
vaccine strain. The HI tests were performed in accordance with
WHO guidelines with established procedures [31,32] using turkey
erythrocytes. In brief, serum samples were pretreated with
receptor destroying enzyme (RDE) from Vibrio cholerae filtrate
(Denka Seiken, Tokyo, Japan) at +37uC for 18 h and then with
100% turkey erythrocytes at +4uC for one hour to remove non-
specific inhibitors and agglutinins. Serial 1:2 serum dilutions
starting from 1:10 initial dilution were made, live viral antigen (4
HA units) was added and incubated for one hour at ambient
temperature. Turkey red blood cells (0.5%) were added to antigen-
serum solutions and incubated at room temperature for 30 min-
utes to determine the HI titers. Serum specimens with HI titers
,10 were assigned a titer value of 5 for statistical analyses.
Statistical analysis
Antibody titers obtained by the HI test were analyzed
statistically by calculating geometric mean titers with 95%
confidence intervals for each virus. Significance of the differences
between mean titers for each virus compared to the vaccine strain
was calculated using Student’s t-test (paired, two-tailed) and the
significance level was adjusted to p,0.01. The correlation
coefficient and the significance of the correlation coefficient of
the antibody titers for each virus were calculated against the A/
California/07/2009 egg-grown virus.
Supporting Information
Figure S1 Amino acid sequence alignment of mature HA
protein of the Finnish influenza A(H1N1)2009 viruses
and some representative A/H1N1 viruses with the
vaccine strain A/California/07/2009. Antigenic sites are
marked as Sa in red, Sb in blue, Ca1 in darker green, Ca2 in
lighter green and Cb in orange. The unchanged amino acids
(compared to A/California/07/2009) are marked with dots and
amino acid changes with corresponding letter. The GenBank
accession numbers of the HA sequences of Finnish strains are
GQ283488, HQ228067-8, HQ228083, HQ228096, HQ228125,
HQ228131, HQ228133, HQ228137, JN601076, JN601088-9,
and JN601091. The accession number for A/California/07/2009
vaccine virus strain is FJ966974, for A/South Carolina/1/18 is
AF117241, A/Puerto Rico/8/1934 is CY033577 and A/New
Jersey/8/1976 is CY039991.
(TIF)
Figure S2 Schematic representation of amino acid
differences in the HA between Finnish influenza
A(H1N1)2009 viruses and the vaccine virus, A/Califor-
nia/07/2009. In the middle of the figure a top view of trimeric
structure of HA molecule of influenza A(H1N1(2009) (A/
California/04/2009; RCSB Protein Bank accession number
3LZG) with previously identified H1 protein-specific antigenic
sites (Sa in red, Sb in blue, Ca1 in darker green, Ca2 in lighter
green and Cb in orange) of influenza A(H1N1) viruses and with
the receptor binding pocket (RBP, purple) is shown. Different
monomers are shown in various shades of grey color. The amino
acid changes of Finnish A(H1N1)2009 viruses compared to A/
California/07/2009, the vaccine strain, are illustrated in the
trimeric HA structure. Amino acid changes in the antigenic sites
are colored as in A/California/04/2009 virus HA molecule.
Amino acid changes outside the expected antigenic sites are shown
in yellow. Changes are illustrated by amino acid residue number
and with serial number of virus where the respective amino acid
change has been observed.
(TIF)
Figure S3 Table of identification codes for the supple-
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